We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CPRX. Catalyst Pharmaceuticals, Inc.’s share was trading at $22.96 as of January 15th. CPRX’s trailing and forward P/E were 13.43 and 10.34 respectively according to Yahoo Finance.
Copyright: dolgachov / 123RF Stock Photo
Catalyst Pharmaceuticals (CPRX) is positioned as a leading rare-disease biopharma with a focused dual-pillar...
